Marsden J, Pedder H, and Santen R; on behalf of The British Menopause Society with acknowledgement to Professor Richard Santen. Risks and benefits of hormone replacement therapy before and after a breast cancer diagnosis. Post Reprod Health. Epub ahead of print 23 July 2020. DOI: https://doi.org/10.1177/2053369120934026
Due to an administrative error, this article was accidentally published Online First and in Volume 25, Issue 1 with different DOIs. This Online First version (above) of this article has been withdrawn by publisher.
The correct and citable version of the article remains:
Marsden J and Pedder H. The risks and benefits of hormone replacement therapy before and after a breast cancer diagnosis. Post Reprod Health 2020; 26(3): 126–135. https://doi.org/10.1177/2053369120956636
References
1.
MorrisECurrieH.Informed choice: is it achievable?Menopause Int2011;
17: 115.
2.
MakamaMDrukkerCARutgersEJT, et al.
An association study of established breast cancer reproductive and lifestyle risk factors with tumour subtype defined by the prognostic 70-gene expression signature (MammaPrint®). Eur J Cancer2017;
75: 5–13.
3.
Collaborative Group on Hormonal Factors for Breast Cancer. Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence. DOI: 10.1016/S0140-6736(19)31709-X.
4.
Collaborative Group on Hormonal Factors for Breast Cancer.Breast cancer and hormone replacement therapy: collaborative reanalysis from 51 individual epidemiological studies. Lancet1997;
350: 1047–1060.
5.
Writing Group for the Women’s Health Initiative Investigators.Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA2002;
288: 321–333.
6.
AndersonGLLimacherMAssafAR, et al;
Women’s Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: The Women’s Health Initiative randomized controlled trial. JAMA2004;
291: 1701–1712.
7.
Million Women Study Collaborators.Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet2003;
362: 419–427.
8.
National Institute for Health and Care Excellence; Menopause; Clinical Guideline – methods, evidence and recommendations (NG23), www.nice.org.uk/guidance/ng23 (2015, accessed 30 January 2020).
9.
SantenRJYueW.Cause or prevention of breast cancer with estrogens: analysis from tumour biological data, growth kinetic model and Women’s Health Initiative Study. Climacteric2019,
22; 3–12.
10.
ShapiroSFarmerRDStevensonJC, et al.
Does hormone replacement therapy cause breast cancer? An application of causal principles to three studies. Part 4: The Million Women Study. J Fam Plann Reprod Health Care2012;
38: 102–109.
11.
GigerenzerG. How innumeracy can be exploited. In: Reckoning with Risk, London, UK: Penguin, 2003.
12.
WangKLiFChenLLaiYM, et al.
Change in risk of breast cancer after receiving hormone replacement therapy by considering effect-modifiers: a systematic review and dose-response meta-analysis of prospective studies. Oncotarget2017;
8: 81109–81124.
13.
The 2017hormone therapy position statement of the North American Menopause Society.Menopause: J N Am Menopause Soc2017;
24: 728–753.
14.
MarsdenJ.NICE guideline – menopause: diagnosis and management. Long-term benefits and risks of HRT (Section 11): breast cancer.J Post Reprod Health2016;
22: 85–91.
15.
JareidMThalabardJCAarflotM, et al.
Levonorgestrel-releasing intrauterine system use is associated with a decreased risk of ovarian and endometrial cancer, without increased risk of breast cancer. Results from the NOWAC Study. Gynecol Oncol2018;
149: 127–132.
16.
SoiniTHurskainenRGrénmanS, et al.
Levonorgestrel-releasing intrauterine system and the risk of breast cancer: a nationwide cohort study. Acta Oncol2016;
55: 199–192.
17.
YangZHuYZhangJ, et al.
Estradiol therapy and breast cancer risk in perimenopausal and postmenopausal women: a systematic review and meta-analysis. Gynecol Endocrincol2017;
33: 87–92.
18.
The British Menopause Society consensus statement on the management of women with premature ovarian insufficiency, www.thebms.org.uk (2017, accessed December 2019).
19.
JaakkoloSLyytinenHPukkalaE, et al.
Endometrial cancer in postmenopausal women using estradiol-progestin therapy. Obset Gynecol2009;
114: 1197–1204.
20.
CrandallCJHoveyKMAndrewsCA, et al.
Breast cancer, endometrial cancer, and cardiovascular events in participants who used vaginal estrogen in the Women’s Health Initiative Observational Study. Menopause2018;
25: 11–20.
21.
CheblowskiRTThomasREMansonJE, et al.
Breast cancer after use of estrogen plus progestin and estrogen alone. JAMA2015;
3: 296–305.
22.
BrownKFRumgayHDunlopC, et al.
The fraction of cancer attributable to modifiable risk factors in England, Wales, Scotland, Northern Ireland, and the United Kingdom in 2015. Br J Cancer2015;
118: 1130–1140.
23.
MansonJEChlebowskiRTStefanickML, et al.
The Women’s Health Initiative hormone therapy trials: update and overview of health outcomes during intervention and post-stopping phases. JAMA2013;
310: 1353–1368.
24.
SuzukiROrsiniNSajiS, et al.
Body weight and incidence of breast cancer defined by estrogen and progesterone receptor status–a meta-analysis. Int J Cancer2009;
124: 698–672.
25.
HamajimaNHiroseKTajimaK, et al.
Alcohol, tobacco and breast cancer–collaborative reanalysis of individual data from 53 epidemiological studies, including 58,515 women with breast cancer and 95,067 women without the disease. Br J Cancer2002;
87: 1234–1245.
26.
www.ons.org.uk deathsummarytables2017final-2 (2017, accessed 9 December 2019).
27.
BeralVPetoRPirieK, et al.
Menopausal hormone therapy and 20-year breast cancer mortality. Lancet2019;
394: 1139.
28.
YuXZhouSWangJ, et al.
Hormone replacement therapy and breast cancer survival: a systematic review and meta-analysis of observational studies. Breast Cancer2017;
24: 643–657.
29.
MansonJEAragakiAKRossouwJE, et al.; WHI Investigators.
Menopausal hormone therapy and long-term all-cause and cause-specific mortality: The Women’s Health Initiative Randomized Trials. JAMA2017;
318: 927–938.
30.
ColleoniMSunZPriceKN, et al.
Annual hazard rates of recurrence for breast cancer during 24 years of follow-up: results from the International Breast Cancer Study Group Trials I to V. J Clin Oncol2016;
34: 927–935.
31.
HolmMOlsenAYeungSLA, et al.
Pattern of mortality after menopausal hormone therapy: long-term follow up in a population-based cohort. BJOG2019;
126: 55–63.
32.
SarrelPMNjikeVJVinanteV, et al.
The mortality toll of estrogen avoidance: an analysis of excess deaths among hysterectomized women aged 50 to 59 years. Am J Public Health2013;
103: 1583–1588.
33.
National Institute for Health and Care Excellence; Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer (CG164), www.nice.org.uk/guidance/cg164 (2013, accessed December 2019).
34.
GordhandasSNorquistBMPenningtonKP, et al.
Hormone replacement therapy after risk reducing salpingo-oophorectomy in patients with BRCA1 or BRCA2 mutations; a systematic review of risks and benefits. Gynecol Oncol2019;
153: 192–200.
35.
National Institute for Health and Care Excellence; Early and locally advanced breast cancer: diagnosis and treatment. NICE guidelines [NG101], www.nice.org.uk/guidance/ng101/resourses (2018, accessed December 2019).
36.
SwainSMWilsonJWMamounasEP, et al.
Estrogen receptor status of primary breast cancer is predictive of estrogen receptor status of contralateral breast cancer.JNCI2004;
96: 516–523.
37.
KarlssonELindströmLSWilkingU, et al.
Discordance in hormone receptor status in breast cancer during tumor progression. J Clin Oncol2010;
28: 1009–1009.
38.
MarsdenJMordenJA’HernR, et al.on behalf of the UK HRT Trial Management Group. Hormone replacement therapy (HRT) is effective in relieving oestrogen deficiency symptoms (ODS) and improves quality of life in breast cancer patients: the UK randomised HRT trial experience. Maturitas2017;
100; 132.
39.
KenemansPBundredNJFoidartJM, et al.;
LIBERATE Study Group. Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms: a double-blind, randomised, non-inferiority trial. Lancet Oncol2009;
10: 135–146.
